Circulating tumor cells in stratification of patients in clinical trials
Thursday, August 29,
8AM PDT | 11AM EDT | 4PM BST | 5PM CEST
If you've already registered, please click here to log in to the webcast.
Detection and investigation of circulating tumor cells (CTCs) is at the forefront of precision medicine in cancer prognosis and treatment. This webinar will showcase how Epic Sciences’ CTC platform, using Functional Cell Profiling (FCP) technology, can assist in stratifying patient populations in observational or interventional studies, with an emphasis on prostate and breast cancer.
The highly sensitive cellular and molecular biomarker analyses can detect CTCs and identify tumor-related abnormalities which could affect patients’ therapeutic response—helping to identify those most likely to respond, or who have novel phenotypic characteristics associated with response/resistance. Epic’s platform uses proprietary sample preparation methods to reduce preanalytical variables, as well as computer vision to collect digital pathology data to enable individual cell investigation and additional downstream analysis of phenotypic heterogeneity, genomic instability, and single cell sequencing. Epic Sciences works with investigators at cancer centers and pharmaceutical companies to pair rare cell types, both genotypically and phenotypically, with patient outcomes.
During this webcast you will learn:
- How the FCP liquid biopsy platform provides insight into patient identification using a CTC-based biomarker analysis in lieu of difficult to obtain tissue biopsy.
- Our unique method of capturing the same protein biomarkers seen with tissue biopsy.
- Medical applications, including how FCP highlights emerging resistant mechanisms and whether those are targetable by approved drugs or eligible for clinical trials.
Produced for Epic Sciences by Nature Research Custom Media, which operates independently of other Nature Research editorial departments. The sponsor retains sole responsibility for content. About this content.